Asunción, IP Agency.- The arrival of bivalent vaccines against covid-19 will allow the immunization process to continue and its implementation on an annual basis, with greater follow-up during the winter season.
These vaccines protect against two variants of the virus that causes covid-19: the original variant and the so-called omicron. In its application and monitoring in the United States, no greater risks have been observed for the population than with the application of previous vaccination schemes.
The Center for Disease Control and Prevention (CDC) of this country reported that “it is very unlikely” that they represent a true clinical risk, referring to the bivalent vaccines from the Pfizer-BioNTech and Moderna laboratories, reported the Ministry of Health.
The vaccines that arrived in the country on Friday, January 27, correspond to those of the Moderna laboratory, acquired by the Paraguayan Government. They will be distributed in all health regions and the Ministry’s objective is to apply these vaccines annually instead of the current schedule of two doses plus booster vaccines starting in the fourth month.
Vaccine Safety
The Expanded Immunization Program (PAI) carries out the monitoring of possible serious events, the result of the application of vaccines against covid-19.
Of the total doses applied, 0.004% required an observation period when observing fevers, fainting spells, allergies in the area of application and a history of epilepsy due to fever among those vaccinated.
This means that 469 cases of the more than 9.5 million doses applied represented mild symptoms and at no time were serious events attributable to vaccination observed.
